In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Antisoma adopts Therex from Imperial Cancer Research Fund
Antisoma licenses rights to develop Betagenon’s AMPK activators as cancer treatments
Antisoma presents Phase II Theragyn data in ovarian cancer
Cancer Research Technology and The Institute of Cancer Research complete licence with Vernalis
Oxigene/Cancer Research UK collaborate on cancer treatment
Coley to collaborate with Ludwig Institute for Cancer Research
Antisoma to evaluate rainforest anti-cancer compounds from EcoBiotics Ltd